Css LLC United Therapeutics Corp Transaction History

Css LLC

  • $999 Million
  • Q3 2024

A detailed history of Css LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Css LLC holds 2,047 shares of UTHR stock, worth $738,700. This represents 0.07% of its overall portfolio holdings.

Number of Shares
2,047
Previous 1,747 17.17%
Holding current value
$738,700
Previous $556,000 31.83%
% of portfolio
0.07%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$311.04 - $363.55 $93,312 - $109,065
300 Added 17.17%
2,047 $733,000
Q2 2024

Aug 14, 2024
SELL
$228.26 - $319.04 $114,814 - $160,477
-503 Reduced 22.36%
1,747 $556,000
Q1 2024

May 15, 2024
SELL
$210.76 - $249.51 $63,228 - $74,853
-300 Reduced 11.76%
2,250 $516,000
Q4 2023

Feb 14, 2024
BUY
$214.88 - $256.94 $21,488 - $25,694
100 Added 4.08%
2,550 $560,000
Q3 2023

Nov 14, 2023
SELL
$211.82 - $248.24 $74,137 - $86,884
-350 Reduced 12.5%
2,450 $553,000
Q2 2023

Aug 14, 2023
BUY
$205.19 - $232.99 $61,557 - $69,897
300 Added 12.0%
2,800 $618,000
Q1 2023

May 15, 2023
BUY
$212.99 - $276.17 $149,093 - $193,319
700 Added 38.89%
2,500 $559,000
Q4 2022

Feb 14, 2023
SELL
$205.95 - $280.43 $20,595 - $28,043
-100 Reduced 5.26%
1,800 $500,000
Q3 2022

Nov 14, 2022
SELL
$203.3 - $244.17 $81,320 - $97,668
-400 Reduced 17.39%
1,900 $398,000
Q2 2022

Aug 15, 2022
BUY
$174.81 - $241.14 $52,443 - $72,342
300 Added 15.0%
2,300 $542,000
Q1 2022

May 16, 2022
BUY
$166.16 - $213.96 $332,320 - $427,920
2,000 New
2,000 $359,000

Others Institutions Holding UTHR

# of Institutions
671
Shares Held
42.3M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email